Explore the new AI foundation model by Insilico Medicine and Liquid AI for efficient pharmaceutical research on private ...

A team of scientists has identified an enzyme called PurF as a new drug target for tuberculosis, offering a fresh line of ...

Explore the promising early results of PRI-101, a new treatment for Parkinson's disease aimed at targeting neurodegeneration.

Researchers developed FLAV-27, an epigenetic drug that inhibits G9a to restore gene expression in Alzheimer’s models. The ...

Drug discovery has traditionally been a reductive process—narrowing down, filtering out, and optimizing within established constraints. Generative AI turns that on its head. It is an expansive force, ...

Researchers from Imperial and the London School of Hygiene & Tropical Medicine (LSHTM) have discovered a drug target that ...

About Insilico Medicine: Insilico Medicine is a clinical-stage biotechnology company using AI for drug development across cancer, fibrosis, immunity, central nervous system diseases, and aging-related ...

A multinational research team led by researchers at Institute of Science Tokyo, RIKEN, and the University of Toronto has revealed how a tryptophan-rich allosteric communication network regulates ...

Genetically-humanized FcRn mice provide translational pharmacokinetics (PK) and pharmacodynamics (PD) data for antibody-based therapeutics. The image illustrates a therapeutic antibody (blue) adhering ...

A new drug delivery approach uses modified Listeria monocytogenes to target colorectal cancer and improve pre-clinical outcomes.